Lupin gets USFDA nod for diabetes management drug
Lupin today said its US subsidiary-- Lupin Pharmaceuticals Inc-- has received final approval from the the US Food and Drugs Administration to market generic diabetes management drug Pioglitazone Tablets in the American market.
The company will shortly commence marketing the product, it said in a regulatory filing.
The approval has been granted for tablets in strengths of 15 mg, 30 mg and 45mg.
''Lupin's Pioglitazone tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings,'' the firm said.
(Posted on 09-04-2014)